In addition, breast cancer patients with an inherited TP53 mutation are more likely to present with amplification of HER2[38], and TP53 mutations result in expansion of primary premalignant mouse mammary stem cells[1]. This evidence concerns the gene ERBB2 and breast carcinoma.